Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
CytoDyn Inc. has closed $16.5 million in financing to support the development of leronlimab. This funding reflects strong investor confidence in the company's clinical progress.
CytoDyn Inc. announced the closure of a $16.5 million financing, led by Paulson Investment Company as placement agent. The funds will primarily support clinical development programs and other operational needs. This successful financing highlights strong investor commitment to CytoDyn's growth strategy
Company Information
Company
CytoDyn
Location
1111 Main Street
Vancouver, Washington, United States
About
CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation.
Don't miss CytoDyn's next move
Get an email the moment CytoDyn raises, hires an exec, or expands, usually minutes after it happens.
VancouverBiotechnologyHealthcareHealth CareTherapeutics